Agios制药 AGIO 深 沪
交易中 04-01 10:14:20 美东时间
36.12
+2.290
+6.77%
华盛通- 最 高36.15
- 今 开33.93
- 成交量 15.95万股
- 最 低 33.89
- 昨 收 33.83
- 总市值 21.16亿
- 52周最高 46.00
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 22.24
- 委 比 98.80%
- 总股本 5859.22万
- 历史最高 138.85
- 量 比 1.51
- 振 幅 6.68%
- 历史最低 15.77
- 每 手 1
- 风险率 5.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?
.Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease.
今天 00:39
Agios Pharmaceuticals Says It Will Pursue US Accelerated Approval For Mitapivat For Sickle Cell Disease
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will pursue U.S. accelerated
03-31 19:05
美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元
02-13 15:30
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $65
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $62 to $65.
02-13 03:01
财报速睇 | Agios制药 2025财年Q4营收0.20亿美元，同比增长86.9%；归母净利润亏损1.08亿美元，同比亏损扩大11.9%
华盛资讯2月12日讯，Agios制药公布2025财年Q4业绩，公司Q4营收0.20亿美元，同比增长86.9%，归母净利润亏损1.08亿美元，同比亏损扩大11.9%。
02-12 19:49
Earnings Summary: Agios Pharmaceuticals Q4
The earnings results for Agios Pharmaceuticals (NASDAQ:AGIO) for Q4 were made p...
02-12 19:36
Agios Pharmaceuticals Q4 EPS $(1.86) Beats $(1.94) Estimate, Sales $19.967M Beat $12.014M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(1.94) by 3.93 percent. This is a 4.12 percent increase over losses of $(1.94) per share
02-12 19:35
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
